welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Global Rare Disease Group’s Focus: 1,000 New Therapies by 2027, Despite COVID-19


Even with the coronavirus pandemic ravaging Europe and much of the world, patient advocate Lucia Monaco, PhD, of Italy remains confident that the Paris-based nonprofit she chairs will see the approval of 1,000 new rare disease therapies by 2027.

That group, the International Rare Diseases Research Consortium (IRDiRC) — launched in 2011 by the European Union and the U.S. National Institutes of Health (NIH) — falls under the umbrella of the European Joint Programme on Rare Diseases (EJP RD).

The IRDiRC had planned to host 200 experts at a March 12–13 rare disease conference in Berlin. But, like every other medical event in Europe, that much-anticipated gathering was canceled in the wake of an explosion of infections and deaths across the 27-member EU. According to published reports at press time, EU member states account for just over 41% of COVID-19 infections worldwide.

 

Global Rare Disease Group’s Focus: 1,000 New Therapies By 2027, Despite COVID-19